Core Viewpoint - Mounjaro has gained unprecedented attention as an effective solution for sustainable weight loss, initially developed for treating type 2 diabetes, and has proven effective in controlling blood sugar and aiding weight loss [2] Group 1: Clinical Trial Data - Mounjaro's effectiveness is highlighted by the SURMOUNT-5 phase 3b clinical trial, where participants lost an average of 50.3 pounds (22.8 kg) over 72 weeks [4] - Experts in obesity medicine regard Mounjaro as a groundbreaking drug that effectively combines weight loss and metabolic health improvement [4] Group 2: Mechanism of Action - Mounjaro employs a dual-target mechanism, utilizing GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) to regulate appetite, improve blood sugar control, and enhance fat reduction [5] - This multi-target approach is believed to contribute to the long-term effectiveness of weight management for many patients [5] Group 3: Health Benefits Beyond Weight Loss - Mounjaro has shown improvements in metabolic indicators such as blood pressure, blood lipids, BMI, and waist circumference, which are critical risk factors for cardiovascular diseases [6] - The drug has been approved for treating moderate to severe obstructive sleep apnea (OSA) in obese adults, linking weight loss to potential benefits for OSA patients [8] - Positive results from the SUMMIT study indicate that Mounjaro significantly reduces the risk of heart failure in patients with preserved ejection fraction [8] Group 4: Future Outlook - The obesity epidemic poses significant health risks and economic burdens, with studies indicating that individuals with a BMI of 40-50 kg/m² have only a 50% chance of living to 70 years old [11] - Effective weight loss interventions can significantly reduce the risk of related complications, such as type 2 diabetes and sleep apnea, by over 50% for patients without existing complications [11] - Experts believe that advancements in weight loss science may lead to a turning point in the battle against obesity [11]

Core Viewpoint - Eli Lilly (LLY) is positioned as a strong long-term investment opportunity in the obesity treatment market, particularly with its GLP-1 drugs, despite potential competition and earnings growth slowdown risks. Group 1: Market Performance and Resilience - Eli Lilly's stock has shown relative resilience compared to the broader market, with a 19% decline during the 2022 inflation shock and a 23% decline during the 2020 COVID-19 pandemic, while the S&P 500 experienced declines of 25% and 34% respectively [2] - LLY stock has already absorbed significant impacts, falling over 20% from its 52-week high of over $970 to below $750 [3] Group 2: Market Potential and Competitive Position - The market for GLP-1 drugs is projected to grow to $150 billion by 2030, with Eli Lilly and Novo Nordisk currently dominating, having generated over $40 billion in sales last year [3] - Eli Lilly is a leader in the obesity treatment race, with superior efficacy and multiple product offerings, including injectable Zepbound and promising oral GLP-1 formulations showing nearly 8% weight loss in trials [3] Group 3: Financial Performance and Stability - Eli Lilly's growth rate is accelerating at over 30%, significantly higher than AbbVie's under 5%, with a three-year average growth rate of 17% compared to AbbVie's less than 1% [6] - Eli Lilly's three-year average margins stand at 34%, superior to AbbVie's 26%, indicating better profitability [6] - Eli Lilly's balance sheet is stronger, with debt making up only 4% of equity compared to AbbVie's 20%, signaling a healthier financial standing [6]

整理 | GLP1减重宝典内容团队 再生元制药公司（NASDAQ: REGN）宣布与翰森制药集团有限公司（"翰森制药"）达成许可协议，再生元获得GLP-1/GIP双重受体激动剂 （HS-20094）在中国大陆、香港和澳门以外地区的独家临床开发和商业化权利。 该候选药物目前正处于三期临床试验阶段，作为每周一次的皮下注射方案，已在超过1,000名患者中进行测试，显示出良好的安全性和疗效，其 表现与目前美国FDA唯一批准的GLP-1/GIP双重受体激动剂相似。目前，该药正在中国进行一项治疗肥胖的三期临床试验以及一项糖尿病二期b 试验。 根据协议条款，再生元将向翰森制药支付8000万美元的预付款，并在开发、监管及销售里程碑达成时，可能额外支付最高19.3亿美元。此外，在 协议指定地区以外的全球销售收入中，翰森制药还将获得低双位数百分比的销售提成。 再生元内科临床开发高级副总裁Boaz Hirshberg医学博士补充道："获得这一处于后期开发阶段的药物，使我们有机会将其与自有在研药物进行 联合探索，进一步解决肌肉流失以及心血管疾病、肝脏疾病和糖尿病等肥胖并发症。这也与我们在肥胖治疗领域的整体战略相一致，例如我们正 在进 ...

Core Viewpoint - The article highlights the significance of the GLORY-1 clinical trial for the innovative weight-loss drug, Ma Shidu Tie (IBI362), which is a dual receptor agonist targeting glucagon (GCG) and glucagon-like peptide-1 (GLP-1). This trial is notable for being the first of its kind to be published in a prestigious medical journal, the New England Journal of Medicine, despite not being the first dual-target GLP-1 drug to undergo clinical research globally [1][2][3]. Group 1: Clinical Research and Results - The GLORY-1 study involved 610 participants and demonstrated that Ma Shidu Tie significantly reduced body weight compared to a placebo, with 73.9% and 82.0% of participants in the 4mg and 6mg groups, respectively, achieving a weight loss of ≥5% by week 32, compared to only 10.5% in the placebo group [4]. - By week 48, the proportions of participants achieving a weight loss of ≥15% were 35.7% and 49.5% for the 4mg and 6mg groups, respectively, versus 2.0% for the placebo group [4]. - The study also found that Ma Shidu Tie significantly lowered cardiovascular metabolic indicators, including blood pressure, blood lipids (triglycerides, total cholesterol, and low-density lipoprotein cholesterol), uric acid levels, and liver enzyme levels, while also reducing liver fat content in patients with fatty liver disease [4]. Group 2: Market Context and Competition - Ma Shidu Tie is being developed and commercialized in China by Innovent Biologics, having obtained rights from Eli Lilly, which also developed the first approved dual-target GLP-1 drug, Tirzepatide, that was launched in China earlier this year [2][3]. - The competitive landscape indicates that both Ma Shidu Tie and Tirzepatide will be vying for market share in the weight-loss drug segment in China, with Ma Shidu Tie expected to be approved for sale by 2025 [5]. - The pricing of Tirzepatide has been noted, with costs ranging from approximately 2,180 yuan to 4,980 yuan per box, which is significantly higher than Novo Nordisk's single-target GLP-1 agonist, Semaglutide, suggesting a differentiated marketing strategy focusing on fat reduction [6].

整理 | GLP1减重宝典内容团队 信达生物宣布，其 GLORY-1 三期临床研究结果在《新英格兰医学杂志》(NEJM) 上发表。该研究评估了玛仕度肽（一种胰高血糖素 (GCG) 和胰高血糖素样肽-1 (GLP-1) 受体双激动剂）在中国超重或肥胖成年患者中的疗效。 该研究的第一作者是北京大学人民医院的纪立农教授和河南科技大学第一附属医院的蒋宏伟教授。纪立农教授和信达生物的钱镭博士 为共同通讯作者。 这是首个提交监管审批的GCG/GLP-1受体双激动剂玛仕度肽的临床试验首次发表在顶级同行评议期刊上。这也标志着中国研发的创 新肥胖治疗药物首次登上《新英格兰医学杂志》(NEJM)，体现了中国在生物制药创新方面的进步。该研究有望为全球肥胖管理临床 指南提供参考。 在NEJM的一篇相关社论中，哈佛大学医学院的Vanita R. Aroda教授和科罗拉多大学安舒茨医学院的Leigh Perreault教授指出了中国 和西方人群在肥胖相关健康结果方面的关键差异。他们强调，中国年轻人出现代谢功能障碍的几率与西方老年人口相当。玛仕度肽不 仅显著降低了体重和BMI，还改善了更广泛的肥胖相关健康指标。他们强调了在中国开展个性化干 ...

整理 | GLP1减重宝典内容团队 罗氏公司于2025年5月11日在ClinicalTrials网站注册了一项名为GYMINDA的II期临床试验，旨在评估RO7204239联合替尔泊肽（tirzepatide） 在肥胖或超重且伴有至少一种体重相关并发症的非糖尿病成人中的疗效、安全性和耐受性。 RO7204239（又称GYM329）是一种由罗氏与中外制药共同开发的肌肉生长抑制素（myostatin，GDF8）单克隆抗体。该药物通过靶向清除血 浆和组织中的潜在性肌抑素（latent myostatin），阻断其被激活为抑制肌肉生长的活性形式，从而有望促进肌肉生长和改善肌肉萎缩相关疾 病。目前，RO7204239正在针对面肩肱型肌营养不良症（FSHD）和脊髓性肌萎缩症（SMA）等疾病开展临床研究。 为期24周的治疗后随访期。 该研究计划招募234名参与者，预计于2025年5月开始，2026年10月初步完成。 替尔泊肽是一种由礼来公司开发的双重GIP和GLP-1受体激动剂，已被批准用于治疗2型糖尿病和肥胖症。在一项为期72周的III期临床试验中， 替尔泊肽每周一次的注射治疗显示出显著和持续的体重减轻效果，平均体重减少 ...

整理 | GLP1减重宝典内容团队 5月11日是"世界防治肥胖日"。近30年来，我国肥胖与超重人群迅速增长，已成为威胁居民健康的重大公共卫生问题。 肥胖不仅是独立 的疾病，也是多种慢性病的重要诱因 ，若不能有效控制，将持续推高相关慢病的发生率。 肥胖问题早已突破个人层面，演变为全球范围的代谢性挑战。世界卫生组织数据显示，2020年全球超重或肥胖人口已超20亿，预计到 2035年将增至33亿。截至2021年，中国25岁以上人群中，超重和肥胖者多达4.02亿，位居全球首位。根据预测， 到2030年，我国成人 和儿童的超重与肥胖率将分别达到70.5%和31.8%，肥胖已成为我国第六大致死致残危险因素。 为应对这一挑战， 国家卫健委于2024年6月联合16个部门共同启动"体重管理年"， 旨在提升公众健康意识，普及科学体重管理理念，从 政策层面强化控肥行动，这也是"健康中国"战略的重要组成部分。 在全球范围内，防控肥胖的措施也正持续推进。《柳叶刀·糖尿病与内分泌学》近日发布一份重要报告，建议在诊断肥胖时将体脂指标 （如腰围、腰臀比、腰高比或体脂含量）与体质指数（BMI）结合使用，以降低误判风险。这一新型诊断方法不仅提升 ...

Financial Data and Key Metrics Changes - Fourth quarter revenue was $5.6 million, down from $8.2 million in the same period in 2023, primarily due to the temporary suspension of sales in France and macroeconomic headwinds [28] - Full year revenue for 2024 was $32.1 million, in line with pre-announcement expectations [17] - Gross profit for Q4 2024 was $2.5 million, or 45% of revenue, compared to $6.4 million, or 78% of revenue in Q4 2023 [29] - Operating expenses in Q4 decreased by 39% year-over-year, driven by restructuring and reorganization efforts [18] Business Line Data and Key Metrics Changes - Procedure volumes grew by 4% in 2024, higher than previously issued guidance, attributed to patients entering the funnel after trying and stopping GLP-1 medications [18] - Sales and marketing expenses for Q4 2024 were $7.9 million, down from $10.7 million in Q4 2023, including $3.1 million of restructuring costs [30] - Research and development expenses for Q4 2024 were $4.1 million, down from $6.1 million in Q4 2023, also including restructuring costs [31] Market Data and Key Metrics Changes - The U.S. market represents a significant opportunity due to high obesity rates and widespread use of GLP-1s, with over 40% of adults in the U.S. classified as obese [24] - The company expects to see the highest procedural volume increases in regions where GLP-1s are most mature, indicating a trend of patients returning for alternative treatments after discontinuing GLP-1s [46] Company Strategy and Development Direction - The company’s strategy for 2025 is built around five pillars, including a new commercial plan focused on key geographies, gaining FDA approval for the Allurion Balloon, achieving profitability for the ex-U.S. business, scaling the AI product platform, and resuming commercialization in France [19] - The company plans to launch additional prospective studies to confirm initial findings on the combination of the Allurion Balloon with low-dose GLP-1s, aiming to define a new paradigm in obesity care [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum building in Q1 2025, with procedure volumes on track to increase by over 30% compared to Q4 2024 [22] - The company anticipates operating expenses to decline by approximately 50% in 2025 compared to 2024, while still investing in key growth areas [24] - Management highlighted the importance of the clinical data generated on the combination therapy, which could redefine obesity management standards [35] Other Important Information - The company raised additional capital through financings, providing a cash runway into 2026 and through expected FDA approval [26] - The company resumed sales in France after regulatory review, which is expected to contribute to future revenue growth [26] Q&A Session Summary Question: Follow-up on results using balloons with low-dose GLP-1 - Management explained that the positive results were driven by using lower doses of GLP-1, which protects lean body mass while still achieving weight loss through synergistic mechanisms [41][42] Question: Key assumptions for 2025 guidance of $30 million - Management indicated confidence in preserving procedure volumes and highlighted the importance of regions where GLP-1s are mature for future growth [44][46] Question: Progress on U.S. approval timeline - The next milestone is completing the PMA submission in the first half of the year, with updates to follow [49] Question: Trends in procedure volume growth - Management confirmed that momentum is continuing in markets where GLP-1s are mature, with significant growth observed in pilot accounts [55] Question: Cadence of revenue to reach $30 million - Management expects a steady build of revenue quarter-over-quarter, driven by the new commercial plan and an increase in the sales team [80][82] Question: Timing for meaningful contribution from France - Management does not expect a material contribution from France until late 2025 or early 2026 due to the time required to reengage with accounts [85] Question: Gross margin recovery expectations - Management anticipates a quicker recovery in gross margin than revenue build, starting in Q1 2025 [87] Question: Impact of launching the smaller balloon on margin - Management does not expect significant impact on gross margin from the next-gen balloon in 2025, but potential for expansion in 2026 [90]